Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD
Mar 31, 2020•over 5 years ago
Description
Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced an equity investment from CureDuchenne Ventures. The funding will support Dyne’s development of precision therapeutics designed to restore muscle health in people living with Duchenne muscular dystrophy (DMD).